The diagnostic landscape for autoimmune disorders is undergoing a seismic shift. As the primary screening tool for conditions like Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), the Anti-Nuclear Antibody (ANA) Test Market is expanding rapidly. Driven by a global rise in autoimmune prevalence and a new era of laboratory automation, the market is moving from manual mi... https://shashikant873.livejournal.com/3767.html